06
Feb
Client News: Legacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Member of the Roche Group
EXCERPT George Town, Cayman Islands, February 06, 2025 –(PR.com)– Legacy Pharma Inc. SEZC (“Legacy Pharma” or the “Company”), a specialty pharmaceutical company, announced the completion of the acquisition of InterMune, Inc. (“InterMune”) and the intellectual property rights to Esbriet® (pirfenidone) in…
30
Nov
Client News: Legacy Pharma Acquires Naftin® and Other Products from Sebela Pharmaceuticals
EXCERPT November 2024 – Post of the acquisition from Legacy Pharma CEO, Mark Thompson “Very pleased to announce that Legacy has acquired a basket of products from Sebela Pharmaceuticals including Naftin. After this acquisition, Legacy has 22 prescription products sold…
01
Oct
Client News: Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
EXCERPT Tuesday, 01 October 2024 08:00 AM Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / ACCESSWIRE / October 1, 2024 / Aytu…
22
Apr
Client News: CHEPLAPHARM announces acquisition of Zyprexa® from Lilly
EXCERPT 04/22/2023 Press releases CHEPLAPHARM announces that it has agreed on 21st April with Eli Lilly and Company on the acquisition of the worldwide[1] commercial rights for Zyprexa®. The subject of the transaction is the well-established and positioned olanzapine/olanzapine pamoate monohydrate (“OPM”) portfolio…
12
Apr
Client News: Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
EXCERPT -Potential for up to $452 million in milestone payments with royalties in the mid-twenty percent range-Actinium receives $35 million upfront payment-Immedica obtains exclusive rights to Iomab-B in Europe, the Middle East and North Africa NEW YORK and STOCKHOLM , April 12, 2022 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or…
02
Nov
Client News: Isofol Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Arfolitixorin in Canada
EXCERPT GOTHENBURG, Sweden, Nov. 2, 2020 /PRNewswire/ — Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased to announce today a definitive license agreement with Endo Ventures Limited, a subsidiary of Endo International plc (NASDAQ: ENDP) plc, for the…